nct_id: NCT04058756
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2019-08-16'
study_start_date: '2019-10-30'
study_completion_date: ''
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: PDR001'
long_title: An Open-label, Multi-center Rollover Protocol for Continued Characterization
  of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored
  Spartalizumab Study as Single Agent or in Combination With Other Study Treatments
last_updated: '2025-06-13'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA, Brigette Ma
principal_investigator_institution: Novartis, CUHK
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids:
- ACT020
protocol_no: ''
protocol_target_accrual: 120
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Subject is currently enrolled in a pre-defined Novartis-sponsored study and is
  receiving spartalizumab as single agent or in combination with other study treatment,'
- '* Subject is currently deriving clinical benefit from the study treatment, as determined
  by the investigator.'
- Other protocol defined inclusion criteria may apply
- 'Exclude - Exclusion Criteria:'
- Exclude - * Subject has been permanently discontinued from spartalizumab in the
  parent protocol for any reason other than enrollment in the Roll over Study
- Exclude - * Subject does not meet the criteria specified in the parent protocol
  criteria for continued study treatment.
short_title: Rollover Study for Continued Safety and Tolerability in Subjects Treated
  With Spartalizumab Alone or in Combination With Other Study Treatments
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Novartis Pharmaceuticals
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The purpose of this study is to continue to assess safety and tolerability,
  and to allow continued access to study treatment for subjects already receiving
  spartalizumab as single agent or in combination with other study treatments.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: PDR001
      arm_internal_id: 0
      arm_description: All subjects in all combination will be entered in one arm
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: PDR001'
        level_internal_id: 0
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        oncotree_primary_diagnosis: _SOLID_
